Scarica l'app Stockscreener
3.58
1.38%
-0.05
Dopo l'orario di chiusura:
3.67
0.09
+2.51%
Precedente Chiudi:
$3.63
Aprire:
$3.7
Volume 24 ore:
260.64K
Relative Volume:
0.21
Capitalizzazione di mercato:
$292.35M
Reddito:
$7.05M
Utile/perdita netta:
$-30.43M
Rapporto P/E:
-4.882
EPS:
-0.7333
Flusso di cassa netto:
$21.84M
1 W Prestazione:
+3.77%
1M Prestazione:
+83.59%
6M Prestazione:
+78.11%
1 anno Prestazione:
+195.87%
Intervallo 1D:
$3.4901
$3.75
Intervallo di 1 settimana:
$3.37
$3.80
Portata 52W:
$1.18
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN
ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat
ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire
ProQR Announces Major Share Offering Agreement - TipRanks
There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St
ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM
Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com
ProQR launches public offering to fund RNA therapy research - Investing.com India
ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan
ProQR Therapeutics announces public offering of ordinary shares - MSN
ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance
RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance
RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg
Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times
ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat
Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Best Momentum Stocks to Buy for October 2nd - Yahoo Finance
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India
ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World
ProQR Therapeutics N.V (PRQR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Market Momentum: ProQR Therapeutics N.V (PRQR) Registers a 7.14 Increase, Closing at 1.80 - The Dwinnex
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below Two Hundred Day Moving Average of $1.96 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $1.96 - Defense World
ProQR Announces Webcast Presentation at the 2024 Cantor Global Healthcare Conference - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Above 50-Day Moving Average of $1.90 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Stock Price Crosses Above 50-Day Moving Average of $1.90 - Defense World
A look into ProQR Therapeutics N.V (PRQR)’s deeper side - SETE News
What technical indicators reveal about PRQR stock - US Post News
ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit - Yahoo Finance UK
ProQR Therapeutics NV (FRA:0PQ) Financial Strength : 3 (As of Jun. 2024) - GuruFocus.com
Reviewing ProQR Therapeutics (NASDAQ:PRQR) and OptiNose (NASDAQ:OPTN) - Defense World
ProQR Therapeutics NV (FRA:0PQ) Enterprise Value : €86.81 Mil (As of Aug. 17, 2024) - GuruFocus.com
Comparing Moleculin Biotech (NASDAQ:MBRX) & ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR: Q2 Earnings Snapshot - San Antonio Express-News
ProQR Therapeutics N.V. Financial Performance Review - TipRanks
ProQR Announces Second Quarter 2024 Operating and Financial Results - GlobeNewswire
Virtu Financial LLC Has $59,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Acadian Asset Management LLC Takes $56,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
BNP Paribas Financial Markets Increases Position in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $2.00 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Below Two Hundred Day Moving Average of $2.00 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $2.01 - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Two Hundred Day Moving Average of $2.01 - MarketBeat
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):